Baird analyst David Rescott raised the firm’s price target on Merit Medical (MMSI) to $103 from $102 and keeps an Outperform rating on the shares. The firm updated its model following impressive Q3 results but where volatility remains ahead of its TPT update.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MMSI:
- Merit Medical price target raised to $109 from $105 at Piper Sandler
- Cautious Hold Rating for Merit Medical Systems Amid Strong Q3 and Transitional Challenges
- Merit Medical Systems: Strong Financial Performance and Strategic Growth Drive Buy Rating
- Merit Medical Reports Strong Q3 2025 Growth
- Merit Medical Systems Reports Strong Q3 2025 Results